随着时间的推移,在脏病性囊症中对延迟释放的囊胺的坚持:来自前性CrySTobs队列研究的数据
Chloé Grosyeux1,2, Ségolène Gaillard3,4, Denis Morin5
1Department of Pediatric Nephrology, Rheumatology and Dermatology, University Children's Hospital, Lyon, France. c.grosyeux@chru-nancy.fr.
Pediatric nephrology (Berlin, Germany)
|February 4, 2025
概括
延迟释放的囊胺在两年内在脏病性囊病患者中显示出良好的粘附性. 减少每日摄入量可以改善治疗的坚持性和耐受性,支持其使用.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 罕见疾病 罕见疾病
背景情况:
- 在病性囊病 (NC) 中对囊胺的坚持是一个重大的临床挑战.
- 之前的研究表明,与延迟释放 (DR) 半胺相比,与一年后立即释放 (IR) 配方相比,延迟释放 (DR) 半胺的固性更好.
- 这项研究的目的是评估在两年内DR囊胺的坚持率.
研究的目的:
- 为了评估延迟释放 (DR) 半氨酸在患有脏病性囊症 (NC) 的患者两年的坚持.
- 评估DR囊胺对坚持和生活质量的长期影响.
主要方法:
- 使用药物事件监测系统来评估治疗坚持,得分从0 (差) 到2 (好).
- 每三个月监测一次白细胞囊水平.
- 从一小组患者中收集了关于自我报告的坚持和生活质量的长期随访数据.
主要成果:
- 17名接受DR胺的NC患者被跟踪了两年;中位数的坚持得分为1.62.
- 65%的患者表现出良好的坚持,75%的患者表现出部分或良好的坚持.
- 在基线和两年之间没有观察到白细胞囊水平的显著变化;患者更喜欢每天两次的DR囊胺剂量,而不是每天四次的IR配方.
结论:
- 延迟释放的氨酸在患有脏病性囊病的患者中随着时间的推移表现出相当好的粘附性.
- 减少药物摄入的频率可能会提高患者的药物坚持,并可能减轻副作用.
- 这些发现支持使用DR囊胺作为对囊病患者有益的治疗选择.
相关概念视频
Factors Affecting Renal Clearance: Renal Impairment
48
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
48
Cystic Fibrosis: Management
139
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
139


